CNS Pharmaceuticals, an early stage biotech developing therapies for brain cancer and other CNS tumors, raised $9 million by offering 2.1 million shares at $4, the low end of the range of $4 to $5, to command a fully diluted market value of $67 million. CNS Pharmaceuticals plans to list on the Nasdaq under the symbol CNSP. The Benchmark Company acted as a lead manager on the deal.
